CSI Market
Sign In | Register

Protagenic Therapeutics Inc new (PTIX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PTIX Annual Cash Flow →
This cash flow overview for Protagenic Therapeutics Inc new spans from Jun 30 2025 to Jun 30 2026, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
3 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-0.96
Depreciation & amortization0.01
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Goodwill, Impairment Loss0.01
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.07
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Debtor Reorganization Items Gain Loss On Settlement Of Other Claims Net-
Interest Expense-
Legal Fees Incurred Through Issuance Of Preferred Stock-
Derivative Gain Loss On Derivative Net0.34
Realized Gain Loss On Sale Of Marketable Securities-
Gain On Settlement Of Accounts Payable And Accrued Liabilities-
Adjustment Increase In Note Payable For Acquisition Of Phytanix Bio0.58
Increase Decrease In Value Added Tax Receivable0.03
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Receivables0.00
Increase (Decrease) in Accounts Payable0.05
Increase (Decrease) in Accrued Liabilities-0.01
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.11
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.22
Discontinued operations0.00
Net Cash flow from Operating Activities-0.94
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments for (Proceeds from) Previous Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Bridge Loans-
Warrants Issued For Placement Agent-
Warrants Issued For Settlement And Conversion Of Debt-
Settlement Of Debt By Issuance Of Series B Preferred Stock-
Reclassification Of Warrants To Derivative Liabilities From Equity-
Accrued Liabilities Paid Through Issuance Of Preferred Stock-
Proceeds From Pik Convertible Debt-
Debt Discount From Issuance Costs On Convertible Notes-
Issuance Of Shares And Warrants From Offering-
Proceeds From Notes Payablerelatedparty-
Debt Discount From Issuance Costs Paid On Pik Convertible Notes-
Proceeds From Notes Payable Related Party-
Issuance Of Shares And Warrants From Offering Net Of Offering Cost-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.94
Total Cash Flow-0.94
4 historic quarters locked

Sign in to unlock the full Protagenic Therapeutics Inc new cash flow history.

Sign In Create Free Account

About Protagenic Therapeutics Inc New Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 19, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-039221

Figures are derived from filed reports and may be restated. Historical data is subject to revision.